Sanofi’s Organizational Restructuring: Investor Insights
On September 13, Sanofi announced a change in two of its GBUs to enable focused operations across emerging markets and mature markets.
Verastem Stock Plunged 19.98% Yesterday
On September 25, Verastem (VSTM) stock fell to $7.15, a ~19.98% fall from its previous close of $8.93.
Opportunities and Competition for J&J’s Blockbuster Drug, Xarelto
Xarelto is a blood thinner developed and commercialized by Johnson & Johnson’s (JNJ) subsidiary, Janssen, and Bayer (BAYZF).
Novo Nordisk’s Biopharmaceuticals Segment: An Update
Novo Nordisk’s (NVO) biopharmaceuticals segment generated revenues of 4.4 billion Danish kroner in the second quarter of 2018.
Johnson & Johnson’s Pulmonary Hypertension Business
In the first quarter, Johnson & Johnson’s Pulmonary Hypertension segment reported revenues of $585.0 million.
How Regeneron’s Praluent and Dupixent Performed in 1Q18
In 1Q18, Regeneron Pharmaceuticals’ (REGN) Praluent reported revenue of $60 million compared to $36 million in 1Q17.
Cabometyx Could Be Exelixis’s Long-Term Growth Driver
In March 2018, the FDA accepted Exelixis’s (EXEL) supplemental New Drug Application (or sNDA) for Cabometyx.
Bayer Completes Sale of Its European Imaging Device Business
On March 6, 2018, Innovatus Imaging completed the acquisition of Bayer’s (BAYZF) MVS (Multi Vendor Service) medical device repair business in Europe.
How Merck’s Women’s Health Segment Performed in 2017
In 4Q17, Merck’s Implanon-Nexplanon reported revenues of $183 million, which was ~14% higher on a YoY basis and a ~18% rise on a QoQ basis.
How Merck’s Cardiovascular Segment Performed in 4Q17 and 2017
In 4Q17, Merck’s Zetia reported revenues of $323 million, which was ~44% lower on a year-over-year basis and a 1% rise on a quarter-over-quarter basis.
How JNJ’s Hypertension Segment Performed in 4Q17
In 2017, Uptravi generated revenues of $236.0 million.
How Pfizer’s Peri-LOE Products Performed in 2017
Pfizer’s (PFE) Peri-LOE products refer to those products that lost patient protection recently or are expected to lose patient protection soon.
How Did Pfizer’s Viagra and Lyrica Perform in 2017?
n fiscal 2017, Pfizer’s (PFE) Viagra reported revenues of $1.2 billion, which represented a ~23% decline on a YoY (year-over-year) basis.
What to Expect from Pfizer’s Xtandi in 2018
In 4Q17, Pfizer (PFE) generated revenues of $168 million from the Xtandi alliance which reflected ~21% growth on a year-over-year basis.
Pfizer’s Sutent Generated Higher Revenues in 4Q17
In the US and international markets in 4Q17, Sutent generated revenues of $96 million and $180 million, respectively.
Analysts’ Updates after Sanofi’s Bioverativ Announcement
In this article, we’ll have a look at Wall Street’s recommendations and target prices following Sanofi’s Bioverativ acquisition announcement.
How Biogen’s Biosimilars and Interferons Performed in 4Q17
In 4Q17, Biogen’s (BIIB) interferons generated revenues of $645 million, which reflected a 6% decline YoY and a 3% decline on a quarter-over-quarter basis.
How Is Bioverativ’s Eloctate Positioned Now?
In 3Q17, Bioverativ’s (BIVV) Eloctate generated revenue of $186.3 million, reflecting a 41% rise on a year-over-year (or YoY) basis.
How Is Roche’s Hemlibra Positioned for 2018?
Roche’s (RHHBY) Hemlibra is used for the prevention and reduction of the frequency of bleeding episodes in individuals with hemophilia A with factor VIII inhibitors.
How Novo Nordisk’s Biopharmaceuticals Segment Performed in 3Q17
In 3Q17, Novo Nordisk’s (NVO) hemophilia segment reported revenues of 2.4 billion Danish krone (or DKK), a ~10% increase on a YoY basis.
How JNJ’s Pulmonary Hypertension Portfolio Performed in 3Q17
In 3Q17, in the US and outside the US (international markets), JNJ’s pulmonary hypertension portfolio generated revenues of $357 million and $283 million, respectively.
How JNJ’s Consumer Products Performed in 3Q17
In 3Q17, Johnson & Johnson’s (JNJ) oral care products generated revenues of $382 million, which reflected a 3% decline quarter-over-quarter.
Regeneron’s Dupixent Approved for Atopic Dermatitis
In March 2017, the US Food and Drug Administration (FDA) approved Sanofi’s (SNY) and Regeneron Pharmaceuticals’ (REGN) Dupixent (dupilumab) for the treatment of individuals with moderate-to-severe atopic dermatitis.
How UTHR’s Remodulin, Adcirca, and Unituxin Performed in 3Q17
In 3Q17, United Therapeutics’ (UTHR) Remodulin reported revenues of $187.3 million, which reflected ~23% growth on a year-over-year (or YoY) basis and ~19% growth on a quarter-over-quarter basis.
How Has Pfizer’s Internal Medicine Portfolio Performed in 2017?
In 3Q17, Pfizer’s (PFE) Lyrica reported revenues of $1.3 billion, which is ~4% growth on a year-over-year (or YoY) basis and 2% growth on a quarter-over-quarter basis.
How 2 Key Novartis Oncology Drugs Performed in 3Q17
In 3Q17, Novartis’s (NVS) Tafinlar-Mekinist generated revenues of $224 million, which was ~30% higher YoY (year-over-year) and 4% higher QoQ.
A Look at Novo Nordisk’s Hemophilia Franchise after 2Q17
In the first half of 2017, Novo Nordisk’s hemophilia franchise reported revenues of DKK 5.3 billion, which reflected a ~1.0% fall on a YoY (year-over-year) basis.
How Is Novartis’s Lucentis Positioned after 1H17?
In 1H17, Novartis’s (NVS) Lucentis reported revenues of around $922 million, which is a ~1% decline on a year-over-year (or YoY) basis.
How Novartis’s Promacta, Votrient, and Jakavi Performed in 1H17
In 1H17, Novartis’s (NVS) Promacta/Revolade reported revenues of around $385 million, which reflected ~33% growth on a year-over-year (or YoY) basis.
BioMarin’s Strong Pipeline Could Be a Long-Term Growth Driver
After success in the company’s phase 1/2 trial with BMN 270, an investigational gene therapy for hemophilia A, BioMarin Pharmaceuticals (BMRN) is expected to start phase 3 trials.
How Are Bioverativ’s Key Drugs Positioned after 2Q17?
In 2Q17, Bioverativ’s Alprolix generated revenues of ~$89.7 million, which represents ~12% growth YoY (year-over-year) and ~4% growth sequentially.
How Did United Therapeutics’ Orenitram and Unituxin Perform in 2Q17?
In 2Q17, United Therapeutics’ (UTHR) Unituxin generated revenues of around $16 million, a 10% decline on a year-over-year (or YoY) basis and an 11% decline on a quarter-over-quarter basis.
A Post-2Q17 Look at Pfizer’s Internal Medicines
In 2Q17, Chantix/Champix generated revenues of ~$248 million, which represents ~16% growth on a YoY basis and 4% growth on a quarter-over-quarter basis.
Merck’s General Medicine, Women’s Health, and Animal Health Segments
In 2Q17, Merck’s Animal Health segment generated revenues of ~$955 million, which reflected ~6% growth on a YoY basis and ~2% growth on a quarter-over-quarter basis.
What We May See from Amgen’s Vectibix in 2017
Vectibix’s revenue trends In 2Q17, Amgen’s (AMGN) Vectibix generated revenues of ~$168 million, which represented a ~5% YoY (year-over-year) rise and a ~14% QoQ (quarter-over-quarter) rise. In the US, Vectibix generated revenues of ~$62 million in 2Q17, or ~19% higher YoY. Outside the US, Vectibix reported revenues of ~$106 million, or 2% lower YoY and […]
Gauging Amgen’s Xgeva Contribution in 2017
Xgeva revenue trends In 2Q17, Amgen’s (AMGN) Xgeva generated revenues of ~$395 million, which reflected ~4% growth on a YoY (year-over-year) basis and a 2% decline on a QoQ (quarter-over-quarter) basis. In 2Q17, in the US, Xgeva generated revenues of ~$292 million, which reflected ~6% YoY growth and a ~2% QoQ decline. Outside the US, […]
Dupixent Could Substantially Drive Regeneron’s Growth
In March 2017, the FDA approved Regeneron and Sanofi’s Dupixent injection for the treatment of adult individuals with moderate to severe atopic dermatitis.
Eylea Could Continue to Generate High Revenue
Regeneron Pharmaceuticals (REGN) markets Eylea in the United States, and Bayer (BAYZF) commercializes the drug outside the US market.
How Pfizer’s Internal Medicines Is Positioned in 2017
In 2016, Pfizer’s (PFE) Chantix reported revenues of ~$842 million, which represents a ~25% YoY (year-over-year) rise.
How Merck’s Animal Health Business Is Expected to Perform in 2017
In 2016, Merck’s (MRK) Animal Health segment reported revenues of ~$3.5 billion, which reflected ~4% growth year-over-year.
Biogen’s Interferon Therapies Could Witness Modest Fall in 2017
In 2016, Biogen’s (BIIB) interferon therapies, Avonex and Plegridy, together reported revenues of around $2.8 billion, which reflected a drop of ~6% on a year-over-year (or YoY) basis.
Xgeva Is Expected to See Robust Revenue Performance in 2017
Amgen’s (AMGN) Xgeva was launched commercially in 2010 and is marketed primarily in the US and Europe. The drug crossed the $1 billion annual revenue mark in 2013.
Euro Depreciation and Its Impact on Trade with the US
As the US economy gains strength, its impact on euro trade comes significant.
Sector Composition of the Columbia European Equity Fund
The Columbia European Equity Fund Class A (AXEAX) invests in “equity securities of European companies that are believed to offer growth potential.”
Sector Composition Changes in AXEAX until 1Q16
AXEAX was invested across 69 holdings as of March 2016, seven more than a quarter ago. It was managing assets worth $515.6 million as of March.
How Are the USAA International Fund’s Metrics?
From a purely NAV (net asset value) return standpoint, the USIFX did not have a notable showing in either the one-year period until February 29, 2016, or in 2015.
What Investors Should Know about the USAA International Fund
The USAA International Fund (USIFX) invests at least 80% of its assets in foreign equities.
ARTIX: How Is 2016 Looking so Far for the Fund?
The Artisan International Fund – Investor Class (ARTIX) has been in existence since December 1995.
Understanding DuPont’s High-Margin Agriculture Segment
DuPont’s agriculture segment’s research and development (or R&D) expenses amounted to about 50% of its total R&D expenses in 2014.
How the Columbia European Equity Fund Fared until October
As of the September portfolio of the Columbia European Equity Fund, the top ten equity holdings included Novartis, Roche Holding, and Prudential Financial.
Essentials of the Artisan International Fund (ARTIX)
The Artisan International Fund (ARTIX) requires a minimum initial investment of $1,000. There’s no minimum or specific amount needed to add to an account.
The Columbia European Equity Fund Class A (AXEAX): Historical Overview
The Columbia European Equity Fund seeks capital appreciation by investing in “equity securities of European companies that…offer growth potential.”
German Industrial Production Failed to Regain Strength in August
The Germany industrial production index fell 1.2% in August 2015 against a revised increase of 1.2% in July.
Eurozone Disappoints with Negative Inflation in September
The Eurozone’s annual inflation is expected to fall to -0.10% in September—compared to 0.10% in August. It’s mainly attributed to the fall in energy prices.
A Key Overview of Portola
Portola Pharmaceuticals (PTLA) is a mid-cap stock with a market capitalization of ~$3 billion. It has a weight of 0.28% in the iShares Nasdaq Biotechnology ETF (IBB).
Vanguard European Stock Index Fund Investor Shares (VEURX)
As of August 2015, the Vanguard European Stock Index Fund was managing assets worth a mammoth $20.8 billion.
The Putnam Europe Equity Fund: Class A (PEUGX)
The Putnam Europe Equity Fund has been in operation since September 1990. As of August 2015, the fund was managing assets worth $370.3 million.
Livestock products lead Zoetis’ 3Q14 revenue growth
Zoetis’ operational revenue saw growth across each of its operating segments. The increase was led by the U.S. segment, where revenue grew 7%, to $532 million, driven by sales of livestock products, mainly cattle and swine.
Must-know trends that drive Zoetis’ growth
Demand for Zoetis’ products is driven by a growing population coupled with a rising middle class in emerging markets and increased relocation from rural to urban areas.
Pershing Square takes 8.5% stake in Zoetis
Pershing Square Capital Holdings added a new position in Zoetis Inc. (ZTS), which accounts for 1.52% of Pershing Square’s portfolio for the third quarter that ended in September 2014.
Third Point believes Amgen’s acquisitions should have done more
Faced with expiring patents and increasing competition for its blockbuster drugs, Amgen acquired Onyx to benefit from the latter’s innovative oncology portfolio and pipeline.